334 related articles for article (PubMed ID: 14728015)
1. Drug treatment of combined hyperlipidemia.
Wierzbicki AS; Mikhailidis DP; Wray R
Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
4. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
7. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Brown WV
Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
[TBL] [Abstract][Full Text] [Related]
8. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Zimetbaum P; Frishman WH; Kahn S
J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
10. Optimal therapy of low levels of high density lipoprotein-cholesterol.
Kashyap ML; Tavintharan S; Kamanna VS
Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
[TBL] [Abstract][Full Text] [Related]
11. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
12. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
13. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
14. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
15. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
Koh KK; Quon MJ; Rosenson RS; Chung WJ; Han SH
Int J Cardiol; 2008 Feb; 124(2):149-59. PubMed ID: 17658632
[TBL] [Abstract][Full Text] [Related]
16. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia: associated risks and effect of drug treatment.
Jonkers IJ; Smelt AH; van der Laarse A
Am J Cardiovasc Drugs; 2001; 1(6):455-66. PubMed ID: 14728004
[TBL] [Abstract][Full Text] [Related]
18. Management of diabetic dyslipidemia: need for reappraisal of the goals.
Khera A; McGuire DK
Am J Cardiovasc Drugs; 2005; 5(2):83-91. PubMed ID: 15725039
[TBL] [Abstract][Full Text] [Related]
19. Comparative tolerability of the HMG-CoA reductase inhibitors.
Farmer JA; Torre-Amione G
Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
[TBL] [Abstract][Full Text] [Related]
20. Treatment of dyslipoproteinemia in the metabolic syndrome.
Steinmetz A; Fenselau S; Schrezenmeir J
Exp Clin Endocrinol Diabetes; 2001; 109(4):S548-59. PubMed ID: 11453042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
